ArticleRetrovirology2012
Multiple choices for HIV therapy with integrase strand transfer inhibitors.
Article in Retrovirology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- The impact of routine HIV drug resistance testing in Ontario: A controlled interrupted time series study.PloS one · 2021Article
- An Isoquinoline Scaffold as a Novel Class of Allosteric HIV-1 Integrase Inhibitors.ACS medicinal chemistry letters · 2019Article
- Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens.AIDS (London, England) · 2018Observational
- Effect of HIV-1 Subtype C integrase mutations implied using molecular modeling and docking data.Bioinformation · 2016Article
- Novel 3'-Processing Integrase Activity Assay by Real-Time PCR for Screening and Identification of HIV-1 Integrase Inhibitors.BioMed research international · 2015Article
- Review
- Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV.ACS medicinal chemistry letters · 2014Article
- Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1.ACS medicinal chemistry letters · 2014Article
- Clinically relevant drug-drug interactions between antiretrovirals and antifungals.Expert opinion on drug metabolism & toxicology · 2014Review
- Review
- Article
- Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure.Retrovirology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two integrases inhibitors, raltegravir and elvitegravir, have now been approved by regulatory agencies for use in the treatment of HIV-infected patients; and the approval of a third such drug, dolutegravir, is expected during 2013 on the basis of several phase 3 clinical trials. The advent of this new class of antiretroviral (ARV) medications represents a major advance in the management of HIV infection, and each of these three drugs can be expected to continue to be an important component of ARV combination regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.